The results of imatinib (Gleevec)(formerly STI571) therapy for chronic myeloid leukemia
(CML) have continued to improve and have surpassed almost everyone's predictions …

Evaluations of the 'real-world'efficacy and safety of tyrosine kinase inhibitors in patients with
chronic myeloid leukemia are scarce. A nationwide, population-based, chronic myeloid …

Data from registries suggest that the median age of chronic myelogenous leukemia (CML)
patients is 10–15 years older than that of clinical trials. We conducted a prospective phase II …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

Although imatinib has shown unprecedented efficacy in the treatment of newly diagnosed
chronic-phase chronic myeloid leukemia (CP-CML), approximately one third of patients …

Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for
nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase …

Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed
the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard …

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase
chronic myeloid leukemia: a study of the Spanish PETHEMA group - PMC Back to Top Skip to …

Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …